Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
How Eli Lilly is approaching GLP-1 marketing and what’s next
Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...
中国日报网1d
Innogen's GLP-1 injection approved for treatment of type 2 diabetes in adults
A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...
STAT4d
Lilly expands GLP-1 research to hypertension, neuro conditions
On the company’s earnings call yesterday, Chief Scientific Officer Dan Skrovronsky said it plans to start a Phase 3 trial of its GLP-1 pill, orforglipron, in hypertension. Lilly also plans to ...